Table 4 Microbiological findings and minimal inhibitory concentrations (MICs) of antibiotics used to treat bacterial pathogens detected in respiratory tract samples, blood cultures and other body sites of patients in a study on therapeutic drug monitoring of ceftazidime, piperacillin, meropenem and linezolid in southwest Germany, October 2018–December 2019
Ceftazidime | Piperacillin | Meropenem | Linezolid | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Median MIC (IQR) | S ≤ | R > | Median MIC (IQR) | S ≤ | R > | Median MIC (IQR) | S ≤ | R > | Median MIC (IQR) | S ≤ | R > | |
Respiratory tract infection | ||||||||||||
Enterobacterales (n = 27)a | 1.5 (1–64) | 1 | 4 | – | 8 | 16 | 0.25 (0.25–0.25) | 2 | 8 | – | NA | NA |
Non-fermenters (n = 15)b | 2 (1–3) | 8 | 8 | 136 (16–256) | 16 | 16 | 0.25 (0.25–0.25) | 2 | 8 | – | NA | NA |
Gram-positive cocci (n = 8)c | – | NA | NA | – | NA | NA | –– | NA | NA | 2 (2–2) | 4 | 4 |
Bloodstream infection | ||||||||||||
Enterobacterales (n = 10)a | – | 1 | 4 | 4 (4–66) | 8 | 16 | 0.25 (0.25–0.25) | 2 | 8 | – | NA | NA |
Non-fermenters (n = 3)b | – | 8 | 8 | 4 (4–4) | 16 | 16 | – | 2 | 8 | – | NA | NA |
Gram-positive cocci (n = 13)c | – | NA | NA | – | NA | NA | – | NA | NA | 2 (1.5–5) | 4 | 4 |
Other infections | ||||||||||||
Enterobacterales (n = 10)a | 1 (1–1) | 1 | 4 | 4 (4–4) | 8 | 16 | 0.25 (0.25–1.2) | – | NA | NA | ||
Gram-positive cocci (n = 3)b | – | NA | NA | – | NA | NA | - | NA | NA | 2 (1–2) | 4 | 4 |